Christopher Porter
Concepts (388)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Germ-Line Mutation | 8 | 2022 | 176 | 2.190 |
Why?
| | Genetic Predisposition to Disease | 19 | 2026 | 2350 | 2.170 |
Why?
| | Leukemia | 7 | 2025 | 245 | 2.080 |
Why?
| | Proto-Oncogene Proteins c-ets | 5 | 2022 | 56 | 2.020 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2023 | 293 | 1.840 |
Why?
| | Neoplasms | 16 | 2026 | 2873 | 1.670 |
Why?
| | Hematologic Neoplasms | 3 | 2024 | 163 | 1.570 |
Why?
| | Neoplastic Syndromes, Hereditary | 5 | 2024 | 47 | 1.520 |
Why?
| | Leukemia, Myeloid, Acute | 9 | 2023 | 685 | 1.450 |
Why?
| | Pyrimidines | 6 | 2017 | 519 | 1.450 |
Why?
| | Interleukin-12 | 3 | 2022 | 117 | 1.430 |
Why?
| | Genetic Testing | 7 | 2026 | 480 | 1.350 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 89 | 1.250 |
Why?
| | Repressor Proteins | 5 | 2022 | 428 | 1.180 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 26 | 1.170 |
Why?
| | Thrombocytopenia | 4 | 2020 | 202 | 1.150 |
Why?
| | Pyrazoles | 4 | 2017 | 512 | 1.130 |
Why?
| | Cell Cycle Proteins | 4 | 2017 | 628 | 1.020 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2017 | 431 | 1.020 |
Why?
| | Burkitt Lymphoma | 2 | 2023 | 62 | 0.930 |
Why?
| | Biological Specimen Banks | 1 | 2026 | 105 | 0.900 |
Why?
| | Nuclear Proteins | 3 | 2017 | 741 | 0.890 |
Why?
| | Early Detection of Cancer | 7 | 2026 | 472 | 0.810 |
Why?
| | Hematopoietic Stem Cells | 6 | 2021 | 419 | 0.760 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 1961 | 0.700 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 2 | 2013 | 24 | 0.670 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 729 | 0.640 |
Why?
| | Myelodysplastic Syndromes | 2 | 2024 | 147 | 0.630 |
Why?
| | RNA, Small Interfering | 6 | 2018 | 631 | 0.630 |
Why?
| | Genetic Counseling | 1 | 2020 | 81 | 0.620 |
Why?
| | Cytarabine | 3 | 2017 | 66 | 0.590 |
Why?
| | Child | 31 | 2026 | 22600 | 0.590 |
Why?
| | Gene Knockdown Techniques | 4 | 2019 | 334 | 0.580 |
Why?
| | Cell Line, Tumor | 14 | 2026 | 3523 | 0.570 |
Why?
| | Calcineurin | 1 | 2019 | 105 | 0.560 |
Why?
| | Apoptosis | 9 | 2022 | 2397 | 0.560 |
Why?
| | Pyrimidinones | 5 | 2017 | 125 | 0.550 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2013 | 105 | 0.550 |
Why?
| | Hematologic Diseases | 2 | 2015 | 66 | 0.550 |
Why?
| | Mice | 23 | 2026 | 18261 | 0.540 |
Why?
| | CDC2 Protein Kinase | 1 | 2017 | 27 | 0.530 |
Why?
| | Neoplasm Proteins | 3 | 2021 | 441 | 0.520 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2017 | 35 | 0.520 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 15 | 0.520 |
Why?
| | Registries | 1 | 2026 | 2392 | 0.510 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 19 | 0.510 |
Why?
| | Humans | 71 | 2026 | 144667 | 0.500 |
Why?
| | Thioguanine | 3 | 2013 | 18 | 0.500 |
Why?
| | Phthalazines | 1 | 2017 | 63 | 0.490 |
Why?
| | DNA Repair | 2 | 2017 | 256 | 0.490 |
Why?
| | Antineoplastic Agents | 7 | 2022 | 2201 | 0.490 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2024 | 677 | 0.470 |
Why?
| | Cytokines | 6 | 2023 | 2045 | 0.460 |
Why?
| | Piperazines | 2 | 2017 | 378 | 0.440 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2017 | 532 | 0.440 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 68 | 0.430 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 69 | 0.410 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2026 | 925 | 0.410 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 127 | 0.390 |
Why?
| | Animals | 23 | 2026 | 37948 | 0.380 |
Why?
| | Transduction, Genetic | 1 | 2013 | 131 | 0.370 |
Why?
| | Bone Marrow | 3 | 2022 | 306 | 0.370 |
Why?
| | Drug Synergism | 4 | 2015 | 352 | 0.370 |
Why?
| | Drug Resistance | 2 | 2013 | 145 | 0.360 |
Why?
| | DNA Repair-Deficiency Disorders | 2 | 2024 | 5 | 0.340 |
Why?
| | DNA-Binding Proteins | 3 | 2024 | 1484 | 0.340 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 57 | 0.330 |
Why?
| | Leukemia, Experimental | 1 | 2011 | 27 | 0.330 |
Why?
| | Myeloproliferative Disorders | 1 | 2011 | 20 | 0.330 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2024 | 70 | 0.330 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2017 | 881 | 0.320 |
Why?
| | Genomics | 3 | 2022 | 831 | 0.300 |
Why?
| | Neoplastic Stem Cells | 2 | 2025 | 407 | 0.290 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2009 | 22 | 0.280 |
Why?
| | Influenza Vaccines | 2 | 2004 | 530 | 0.280 |
Why?
| | Vincristine | 1 | 2009 | 140 | 0.280 |
Why?
| | DNA Damage | 4 | 2023 | 430 | 0.270 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2009 | 133 | 0.270 |
Why?
| | Triazoles | 1 | 2009 | 184 | 0.260 |
Why?
| | Flow Cytometry | 4 | 2019 | 1154 | 0.260 |
Why?
| | Cell Separation | 1 | 2008 | 303 | 0.260 |
Why?
| | Purines | 1 | 2008 | 187 | 0.250 |
Why?
| | Female | 24 | 2026 | 78304 | 0.250 |
Why?
| | T-Lymphocytes | 3 | 2026 | 1984 | 0.250 |
Why?
| | Receptors, Vasoactive Intestinal Peptide | 1 | 2026 | 3 | 0.250 |
Why?
| | Vasoactive Intestinal Peptide | 1 | 2026 | 20 | 0.250 |
Why?
| | Immunity, Innate | 2 | 2025 | 843 | 0.230 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2025 | 4 | 0.230 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2025 | 22 | 0.230 |
Why?
| | Medical History Taking | 1 | 2026 | 117 | 0.230 |
Why?
| | Infant | 7 | 2026 | 10023 | 0.230 |
Why?
| | Organ Transplantation | 1 | 2008 | 247 | 0.220 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 915 | 0.220 |
Why?
| | Child, Preschool | 9 | 2026 | 11790 | 0.220 |
Why?
| | Medical Oncology | 3 | 2023 | 331 | 0.220 |
Why?
| | Immune Evasion | 1 | 2025 | 62 | 0.220 |
Why?
| | Mutation | 6 | 2025 | 4081 | 0.210 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1319 | 0.210 |
Why?
| | Single-Cell Analysis | 2 | 2025 | 357 | 0.210 |
Why?
| | Genomic Instability | 1 | 2024 | 67 | 0.210 |
Why?
| | Infant, Newborn | 3 | 2026 | 6399 | 0.200 |
Why?
| | Influenza B virus | 1 | 2004 | 47 | 0.200 |
Why?
| | Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 9 | 0.200 |
Why?
| | Syndrome | 2 | 2023 | 379 | 0.200 |
Why?
| | Y-Box-Binding Protein 1 | 1 | 2023 | 5 | 0.200 |
Why?
| | Signal Transduction | 5 | 2026 | 5185 | 0.200 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5967 | 0.190 |
Why?
| | Interferon-gamma | 2 | 2017 | 781 | 0.190 |
Why?
| | Amides | 1 | 2023 | 99 | 0.190 |
Why?
| | Sulfones | 1 | 2023 | 127 | 0.190 |
Why?
| | Immunoglobulins | 1 | 2023 | 160 | 0.190 |
Why?
| | Thrombopoiesis | 1 | 2022 | 7 | 0.190 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2022 | 6 | 0.190 |
Why?
| | Peutz-Jeghers Syndrome | 2 | 2024 | 10 | 0.180 |
Why?
| | Practice Guidelines as Topic | 3 | 2024 | 1569 | 0.180 |
Why?
| | Germ Cells | 1 | 2022 | 65 | 0.180 |
Why?
| | Adaptive Immunity | 1 | 2023 | 169 | 0.180 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2016 | 217 | 0.180 |
Why?
| | Adenomatous Polyposis Coli | 2 | 2024 | 40 | 0.180 |
Why?
| | Galectins | 1 | 2022 | 27 | 0.180 |
Why?
| | Immunization | 1 | 2004 | 374 | 0.180 |
Why?
| | Adolescent | 10 | 2026 | 22409 | 0.180 |
Why?
| | Thrombopoietin | 1 | 2021 | 5 | 0.170 |
Why?
| | Urogenital Abnormalities | 1 | 2022 | 71 | 0.170 |
Why?
| | Neural Stem Cells | 1 | 2023 | 167 | 0.170 |
Why?
| | Genes, p53 | 2 | 2012 | 67 | 0.170 |
Why?
| | Metabolic Diseases | 1 | 2022 | 114 | 0.170 |
Why?
| | Cerebellar Neoplasms | 1 | 2023 | 177 | 0.170 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 11 | 0.160 |
Why?
| | Young Adult | 7 | 2026 | 14122 | 0.160 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 20 | 0.160 |
Why?
| | Medulloblastoma | 1 | 2023 | 215 | 0.160 |
Why?
| | Patient Education as Topic | 1 | 2026 | 771 | 0.160 |
Why?
| | Mobile Applications | 1 | 2023 | 197 | 0.160 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2021 | 78 | 0.160 |
Why?
| | Family | 2 | 2026 | 685 | 0.160 |
Why?
| | Interferon Regulatory Factors | 1 | 2020 | 44 | 0.160 |
Why?
| | Male | 17 | 2026 | 72431 | 0.150 |
Why?
| | Stem Cell Niche | 1 | 2020 | 57 | 0.150 |
Why?
| | Polymers | 2 | 2023 | 492 | 0.150 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 30 | 0.150 |
Why?
| | Phenotype | 4 | 2023 | 3147 | 0.150 |
Why?
| | Leukemia, Myeloid | 1 | 2019 | 48 | 0.150 |
Why?
| | Antibodies, Bispecific | 1 | 2020 | 69 | 0.150 |
Why?
| | Cell Line | 5 | 2021 | 2821 | 0.150 |
Why?
| | Genotype | 2 | 2022 | 1847 | 0.150 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2022 | 355 | 0.150 |
Why?
| | Up-Regulation | 3 | 2018 | 848 | 0.140 |
Why?
| | Bone Marrow Cells | 1 | 2020 | 321 | 0.140 |
Why?
| | Tumor Escape | 1 | 2019 | 50 | 0.140 |
Why?
| | Histone Deacetylases | 1 | 2020 | 207 | 0.140 |
Why?
| | PAX2 Transcription Factor | 1 | 2018 | 7 | 0.140 |
Why?
| | Osmoregulation | 1 | 2018 | 4 | 0.140 |
Why?
| | PAX5 Transcription Factor | 1 | 2018 | 14 | 0.140 |
Why?
| | Dendritic Cells | 1 | 2022 | 498 | 0.140 |
Why?
| | NADPH Oxidases | 2 | 2017 | 120 | 0.140 |
Why?
| | Lesch-Nyhan Syndrome | 1 | 2018 | 3 | 0.140 |
Why?
| | Anemia, Macrocytic | 1 | 2018 | 4 | 0.140 |
Why?
| | Prospective Studies | 3 | 2026 | 7994 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2023 | 1159 | 0.140 |
Why?
| | Interferon-alpha | 1 | 2019 | 194 | 0.140 |
Why?
| | Cardiomyopathies | 1 | 2022 | 334 | 0.140 |
Why?
| | Personal Satisfaction | 1 | 2020 | 220 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2020 | 227 | 0.140 |
Why?
| | Disease Management | 2 | 2019 | 650 | 0.140 |
Why?
| | Adult | 12 | 2026 | 40489 | 0.130 |
Why?
| | Disease Progression | 2 | 2019 | 2847 | 0.130 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2017 | 16 | 0.130 |
Why?
| | Counseling | 1 | 2020 | 405 | 0.130 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 8 | 0.130 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 31 | 0.130 |
Why?
| | Brain Neoplasms | 2 | 2024 | 1327 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2021 | 961 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 971 | 0.120 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 54 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 465 | 0.120 |
Why?
| | Hepatoblastoma | 1 | 2017 | 52 | 0.120 |
Why?
| | Pediatrics | 2 | 2017 | 1121 | 0.120 |
Why?
| | Cell Proliferation | 3 | 2023 | 2489 | 0.120 |
Why?
| | Wilms Tumor | 1 | 2017 | 86 | 0.120 |
Why?
| | Calcitriol | 1 | 2016 | 57 | 0.120 |
Why?
| | RNA | 1 | 2022 | 926 | 0.110 |
Why?
| | Prednisolone | 1 | 2015 | 66 | 0.110 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1124 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2011 | 4110 | 0.110 |
Why?
| | Immunologic Factors | 3 | 2023 | 259 | 0.110 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2016 | 167 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 985 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2017 | 751 | 0.100 |
Why?
| | DNA Mismatch Repair | 2 | 2024 | 53 | 0.100 |
Why?
| | Dasatinib | 1 | 2014 | 57 | 0.100 |
Why?
| | Blotting, Western | 2 | 2017 | 1161 | 0.100 |
Why?
| | S Phase | 2 | 2012 | 80 | 0.100 |
Why?
| | Hemorrhage | 1 | 2019 | 813 | 0.100 |
Why?
| | Telemedicine | 1 | 2023 | 957 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2003 | 1360 | 0.100 |
Why?
| | Pyridones | 1 | 2015 | 201 | 0.100 |
Why?
| | Thiazoles | 1 | 2014 | 139 | 0.100 |
Why?
| | MAP Kinase Signaling System | 1 | 2015 | 306 | 0.100 |
Why?
| | Cell Cycle Checkpoints | 1 | 2013 | 98 | 0.100 |
Why?
| | Cyclosporine | 1 | 2014 | 255 | 0.100 |
Why?
| | DNA Replication | 2 | 2024 | 252 | 0.100 |
Why?
| | Antigens, CD34 | 1 | 2013 | 88 | 0.100 |
Why?
| | Down Syndrome | 1 | 2019 | 522 | 0.090 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 496 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 1129 | 0.090 |
Why?
| | Umbilical Cord | 1 | 2013 | 92 | 0.090 |
Why?
| | Vitamin D | 1 | 2016 | 400 | 0.090 |
Why?
| | Tankyrases | 1 | 2012 | 13 | 0.090 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 205 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2013 | 146 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 153 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1766 | 0.090 |
Why?
| | Parents | 1 | 2020 | 1395 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1118 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 76 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 284 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2018 | 2037 | 0.090 |
Why?
| | Wnt Proteins | 1 | 2012 | 133 | 0.090 |
Why?
| | Lymphocytes | 1 | 2013 | 379 | 0.080 |
Why?
| | Gene Knock-In Techniques | 1 | 2011 | 60 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 339 | 0.080 |
Why?
| | Inflammation | 1 | 2022 | 2870 | 0.080 |
Why?
| | Kidney | 1 | 2018 | 1495 | 0.080 |
Why?
| | Recurrence | 2 | 2023 | 1136 | 0.080 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 881 | 0.080 |
Why?
| | Aging | 1 | 2021 | 1938 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2012 | 319 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 973 | 0.080 |
Why?
| | Genome, Human | 1 | 2012 | 420 | 0.070 |
Why?
| | Cyclophilin A | 1 | 2009 | 27 | 0.070 |
Why?
| | Basigin | 1 | 2009 | 24 | 0.070 |
Why?
| | Cell Cycle | 2 | 2012 | 595 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2011 | 211 | 0.070 |
Why?
| | Voriconazole | 1 | 2009 | 21 | 0.070 |
Why?
| | ErbB Receptors | 1 | 2012 | 632 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 11 | 0.070 |
Why?
| | Protein Transport | 2 | 2020 | 437 | 0.070 |
Why?
| | Obesity | 1 | 2022 | 3070 | 0.070 |
Why?
| | Lentivirus | 1 | 2008 | 61 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2026 | 4539 | 0.070 |
Why?
| | Protein Folding | 1 | 2009 | 277 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 7122 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1056 | 0.070 |
Why?
| | Genetic Vectors | 1 | 2008 | 334 | 0.060 |
Why?
| | Immunotherapy | 2 | 2021 | 662 | 0.060 |
Why?
| | Calgranulin B | 1 | 2025 | 10 | 0.060 |
Why?
| | Genetic Association Studies | 2 | 2019 | 369 | 0.060 |
Why?
| | Calgranulin A | 1 | 2025 | 11 | 0.060 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 101 | 0.060 |
Why?
| | Risk Assessment | 2 | 2026 | 3729 | 0.060 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2025 | 56 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2026 | 3414 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2007 | 171 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 139 | 0.050 |
Why?
| | Microsatellite Instability | 1 | 2024 | 55 | 0.050 |
Why?
| | MutL Protein Homolog 1 | 1 | 2024 | 11 | 0.050 |
Why?
| | MutS Homolog 2 Protein | 1 | 2024 | 12 | 0.050 |
Why?
| | Cohort Studies | 2 | 2020 | 5957 | 0.050 |
Why?
| | HEK293 Cells | 2 | 2018 | 743 | 0.050 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2004 | 38 | 0.050 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2024 | 40 | 0.050 |
Why?
| | Immunologic Memory | 1 | 2026 | 366 | 0.050 |
Why?
| | B-Lymphocytes | 2 | 2020 | 875 | 0.050 |
Why?
| | Serologic Tests | 1 | 2004 | 53 | 0.050 |
Why?
| | Unrelated Donors | 1 | 2023 | 38 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2942 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2815 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1251 | 0.050 |
Why?
| | Survival Rate | 1 | 2008 | 2089 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2005 | 337 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2004 | 182 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 309 | 0.050 |
Why?
| | Morbidity | 1 | 2023 | 322 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2026 | 339 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2023 | 407 | 0.050 |
Why?
| | Hedgehog Proteins | 1 | 2023 | 197 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 272 | 0.040 |
Why?
| | Receptors, Thrombopoietin | 1 | 2021 | 6 | 0.040 |
Why?
| | Receptors, Cytokine | 1 | 2021 | 36 | 0.040 |
Why?
| | Rare Diseases | 1 | 2022 | 115 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2023 | 342 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2026 | 6041 | 0.040 |
Why?
| | Mice, Nude | 2 | 2014 | 677 | 0.040 |
Why?
| | Mitochondrial Proteins | 1 | 2023 | 262 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 442 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2020 | 34 | 0.040 |
Why?
| | Acute Disease | 1 | 2023 | 1029 | 0.040 |
Why?
| | Middle Aged | 3 | 2019 | 35971 | 0.040 |
Why?
| | CD3 Complex | 1 | 2020 | 111 | 0.040 |
Why?
| | Pilot Projects | 1 | 2026 | 1886 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2020 | 129 | 0.040 |
Why?
| | Prognosis | 1 | 2008 | 4312 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2007 | 826 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2004 | 672 | 0.040 |
Why?
| | Penetrance | 1 | 2019 | 30 | 0.040 |
Why?
| | Protein Binding | 2 | 2020 | 2243 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 733 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 662 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2014 | 11735 | 0.040 |
Why?
| | DNA | 1 | 2005 | 1447 | 0.040 |
Why?
| | Hypertonic Solutions | 1 | 2018 | 7 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2660 | 0.040 |
Why?
| | Transcriptome | 1 | 2025 | 1036 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 619 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2018 | 172 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2018 | 245 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2023 | 652 | 0.030 |
Why?
| | Bloom Syndrome | 1 | 2017 | 3 | 0.030 |
Why?
| | Ataxia Telangiectasia | 1 | 2017 | 18 | 0.030 |
Why?
| | Fanconi Anemia | 1 | 2017 | 11 | 0.030 |
Why?
| | Xeroderma Pigmentosum | 1 | 2017 | 9 | 0.030 |
Why?
| | Muramidase | 1 | 2017 | 66 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2017 | 113 | 0.030 |
Why?
| | Peroxidase | 1 | 2017 | 167 | 0.030 |
Why?
| | Incidence | 1 | 2024 | 2892 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1145 | 0.030 |
Why?
| | Europe | 1 | 2017 | 419 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 360 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2004 | 3603 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 849 | 0.030 |
Why?
| | Phagocytosis | 1 | 2017 | 296 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2015 | 23 | 0.030 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2015 | 28 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2015 | 32 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 190 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2184 | 0.030 |
Why?
| | Oncogenes | 1 | 2016 | 118 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 2015 | 14 | 0.030 |
Why?
| | Vaccination | 1 | 2004 | 1419 | 0.030 |
Why?
| | Beclin-1 | 1 | 2014 | 11 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2014 | 13 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2014 | 20 | 0.030 |
Why?
| | Chloroquine | 1 | 2014 | 53 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 409 | 0.030 |
Why?
| | Exome | 1 | 2015 | 227 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 515 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 1348 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1092 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2017 | 2591 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 185 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2015 | 338 | 0.020 |
Why?
| | Tumor Burden | 1 | 2014 | 324 | 0.020 |
Why?
| | Genes, Synthetic | 1 | 2012 | 14 | 0.020 |
Why?
| | Genes, Lethal | 1 | 2012 | 30 | 0.020 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 20 | 0.020 |
Why?
| | United States | 2 | 2017 | 16018 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5870 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 68 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 473 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3329 | 0.020 |
Why?
| | Doxorubicin | 1 | 2014 | 398 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 466 | 0.020 |
Why?
| | Imidazoles | 1 | 2012 | 246 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2010 | 3109 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 266 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1437 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2010 | 86 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1704 | 0.020 |
Why?
| | Syndecan-1 | 1 | 2009 | 43 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1374 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 293 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 365 | 0.020 |
Why?
| | Lymphoma | 1 | 2010 | 233 | 0.020 |
Why?
| | Catalysis | 1 | 2009 | 319 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 396 | 0.020 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 3 | 0.020 |
Why?
| | Adenoids | 1 | 2007 | 12 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 667 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 849 | 0.020 |
Why?
| | Palatine Tonsil | 1 | 2007 | 55 | 0.020 |
Why?
| | E2F2 Transcription Factor | 1 | 2005 | 14 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1363 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2007 | 323 | 0.010 |
Why?
| | Hydroxyurea | 1 | 2005 | 34 | 0.010 |
Why?
| | E2F1 Transcription Factor | 1 | 2005 | 68 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2007 | 202 | 0.010 |
Why?
| | Precancerous Conditions | 1 | 2007 | 166 | 0.010 |
Why?
| | Biliary Atresia | 1 | 2007 | 158 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2007 | 501 | 0.010 |
Why?
| | Models, Molecular | 1 | 2009 | 1610 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1047 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1186 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 689 | 0.010 |
Why?
| | Risk Factors | 1 | 2017 | 10796 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1705 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2909 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 4261 | 0.010 |
Why?
|
|
Porter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|